Journal
ANNALS OF HEMATOLOGY
Volume 100, Issue 6, Pages 1553-1567Publisher
SPRINGER
DOI: 10.1007/s00277-021-04514-y
Keywords
Multiple myeloma; Allogeneic stem cell transplantation; Survival; Conditioning; Graft-versus-host disease; Post-relapse survival
Categories
Funding
- University of Helsinki
- Helsinki University Central Hospital
- Blood Disease Research Foundation
- Signe and Ane Gyllenberg Foundation.
Ask authors/readers for more resources
The study explored the role of allogeneic hematopoietic stem cell transplantation in multiple myeloma, showing that this approach can lead to long-term survival in a small subgroup of patients, and auto-allo-SCT may be considered for younger patients.
The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000-2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Median overall survival (OS) was 9.9 years for upfront-allo, 11.2 years for auto-allo, and 3.9 years for the relapse group (p = 0.015). Progression-free survival (PFS) was 2.4, 2.4, and 0.9 years, respectively (p < 0.001). Non-relapse mortality at 5 years was 8% overall, with no significant difference between the groups. Post-relapse survival was 4.1 years for upfront-allo and auto-allo, and 2.6 years for the relapse group (p = 0.066). Survival of high-risk patients was reduced. In multivariate analysis, the auto-allo group had improved OS and chronic graft-versus-host disease was advantageous in terms of PFS, OS, and relapse incidence. Late relapses occurred in all groups. Allo-SCT resulted in long-term survival in a small subgroup of patients. Our results indicate that auto-allo-SCT is feasible and could be considered for younger patients in the upfront setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available